Psoriasis vulgaris is managed mainly by employing topical therapies, including steroids and active vitamin D3 formulations, which have been used for many years. Recently, topical combination formulations of steroid and active vitamin D3 have become widely available for clinical use. We reviewed the benefits of these topical combination formulations based on evidence from clinical investigations within and outside Japan, focusing on effectiveness, economics, tolerability, patient's QOL, and adherence. Our review confirmed that topical combination formulations provide rapid efficacy, good tolerability, and improvement of patient's QOL, as well as showing the best cost-benefit performance among the topical therapies currently available. Based on our results, topical combination formulations are recommended as first-line treatment for psoriasis vulgaris.